Company intelligence / Profile preview

Xyall

Eindhoven, North Brabant, Netherlands

Ownership: Private
Development stage: Other

Overview

Xyall’s Tissector platform has launched commercially (HT in late 2022 and TT in late 2023), and is now being rapidly adopted by high-profile molecular pathology labs; the platform enables accurate, automated tissue dissection for molecular diagnostics, improving efficiency and sample quality for oncology testing[5][6][8].

Therapeutic areas: Oncology
Industry: Pathology

Partnerships

Motic (digital pathology/imaging co-development and Asia distribution)[4]Indica Labs (integration with HALO AP software for digital pathology)[8]Sioux Technologies (precision robotics, engineering, early investment)[4][9]

Beyond the preview

Go deeper on Xyall.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xyall.

Explore the full profile